Literature DB >> 21929878

Detection of IgM and IgG anti-Toxoplasma antibodies in renal transplant recipients using ELFA, ELISA and ISAGA methods: comparison of pre- and post-transplantation status.

M J Gharavi1, S Jalali, S Khademvatan, S Heydari.   

Abstract

In the transplant recipient patients receive immunosuppressive therapy, the possibility of reactivation of the old infection or acquisition of infection from a donor's tissue increases. In this study, IgM and IgG anti-Toxoplasma immunoglobulins seroconversion in renal transplant recipients (RTRs) have been evaluated before and after transplantation. This is a prospective cohort study on a total of 102 RTRs. Two serum samples were obtained from each patient. The first was taken before administration of any immunosuppressive drugs such as corticosteroids and the second was taken 3 months after transplantation. The IgM and IgG anti-Toxoplasma antibodies were assayed by enzyme-linked flourescence assay (ELFA) and enzyme-linked immunosorbent assay (ELISA) techniques. IgM/immunosorbent agglutination assay (ISAGA) method has also been used. All RTRs were tested for toxoplasmosis before and after transplantation. ELFA identified 65 (63·7%) pre-transplantation samples as IgG+ and did not detect any positive IgM samples. However, IgM was detected in three (2·9%) post-transplantation samples by this method. Forty-nine (48%) pre-transplantation samples were reported IgG+ by ELISA and no IgM positive sample was identified by this method. ELISA has detected two (1·9%) IgM-positive reactions in post-transplantation samples. By IgM/ISAGA method, we have detected no IgM positive reactions in pre-transplantation samples, whereas 3 months later (second sampling) IgM antibody was detected in 3 (2·9%) cases. Secondary toxoplasmosis infection was observed in 30 cases per 1000 RTRs, which indicates that screening for toxoplasmosis infection should be performed in developed countries for these patients. On the other hand, as the risk of re-active toxoplasmosis infection exists in developing nations, they should consider the necessary preventive measures to control this condition.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21929878      PMCID: PMC4089779          DOI: 10.1179/1364859411Y.0000000022

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  9 in total

Review 1.  Management of toxoplasmosis in AIDS.

Authors:  I Trikha; N Wig
Journal:  Indian J Med Sci       Date:  2001-02

2.  VIDAS test for avidity of Toxoplasma-specific immunoglobulin G for confirmatory testing of pregnant women.

Authors:  Jose G Montoya; Oliver Liesenfeld; Sandra Kinney; Cynthia Press; Jack S Remington
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

3.  Determination of antibodies to Toxoplasma gondii and CMV in renal transplant recipients.

Authors:  J Iqbal; M R N Nampoory; K V Johnv; N Khalid; M Al-Mousawi
Journal:  Transplant Proc       Date:  2003-11       Impact factor: 1.066

4.  European multicenter study of the LIAISON automated diagnostic system for determination of Toxoplasma gondii-specific immunoglobulin G (IgG) and IgM and the IgG avidity index.

Authors:  Eskild Petersen; Maria Victoria Borobio; Edward Guy; Oliver Liesenfeld; Valeria Meroni; Anne Naessens; Emma Spranzi; Philippe Thulliez
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

5.  Toxoplasmosis after renal transplantation: implications of a missed diagnosis.

Authors:  M W H Wulf; R van Crevel; R Portier; C G Ter Meulen; W J G Melchers; A van der Ven; J M D Galama
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

6.  Toxoplasma gondii antibodies in cancer patients.

Authors:  Ziguo Yuan; Shengyan Gao; Quan Liu; Xianzhu Xia; Xiaofeng Liu; Bin Liu; Rongliang Hu
Journal:  Cancer Lett       Date:  2007-03-21       Impact factor: 8.679

Review 7.  Parasitic central nervous system infections in immunocompromised hosts.

Authors:  Melanie Walker; Joseph R Zunt
Journal:  Clin Infect Dis       Date:  2005-03-02       Impact factor: 9.079

8.  Investigation of anti-Toxoplasma gondii antibodies in patients with neoplasia.

Authors:  Süleyman Yazar; Ozan Yaman; Bülent Eser; Fevzi Altuntaş; Fatih Kurnaz; Izzet Şahin
Journal:  J Med Microbiol       Date:  2004-12       Impact factor: 2.472

Review 9.  Toxoplasmosis.

Authors:  J G Montoya; O Liesenfeld
Journal:  Lancet       Date:  2004-06-12       Impact factor: 79.321

  9 in total
  11 in total

1.  Detection of toxoplasmosis in patients with end-stage renal disease by enzyme-linked immunosorbent assay and polymerase chain reaction methods.

Authors:  J Saki; S Khademvatan; S Soltani; H Shahbazian
Journal:  Parasitol Res       Date:  2012-09-20       Impact factor: 2.289

2.  Preventive effect of pidotimod on reactivated toxoplasmosis in mice.

Authors:  Xing-Xing Huo; Lin Wang; Zhao-Wu Chen; He Chen; Xiu-Cai Xu; Ai-Mei Zhang; Xiao-Rong Song; Qing-Li Luo; Yuan-Hong Xu; Yu Fu; Hua Wang; Jian Du; Yi-Hong Cai; Zhao-Rong Lun; Fang-Li Lu; Yong Wang; Ji-Long Shen
Journal:  Parasitol Res       Date:  2013-06-18       Impact factor: 2.289

3.  Experimental infection with the Toxoplasma gondii ME-49 strain in the Brazilian BR-1 mini pig is a suitable animal model for human toxoplasmosis.

Authors:  Farlen José Bebber Miranda; Diogo Benchimol de Souza; Edwards Frazão-Teixeira; Fábio Conceição de Oliveira; João Cardoso de Melo; Carlos Magno Anselmo Mariano; Antonio Peixoto Albernaz; Eulógio Carlos Queiróz de Carvalho; Francisco Carlos Rodrigues de Oliveira; Wanderley de Souza; Renato Augusto DaMatta
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-02-03       Impact factor: 2.743

4.  Toxoplasma gondii Infection in Immunocompromised Patients: A Systematic Review and Meta-Analysis.

Authors:  Ze-Dong Wang; Huan-Huan Liu; Zhan-Xi Ma; Hong-Yu Ma; Zhong-Yu Li; Zhi-Bin Yang; Xing-Quan Zhu; Bin Xu; Feng Wei; Quan Liu
Journal:  Front Microbiol       Date:  2017-03-09       Impact factor: 5.640

Review 5.  A systematic review and meta-analysis of the prevalence of toxoplasmosis in hemodialysis patients in Iran.

Authors:  Masoud Foroutan; Ali Rostami; Hamidreza Majidiani; Seyed Mohammad Riahi; Sasan Khazaei; Milad Badri; Elham Yousefi
Journal:  Epidemiol Health       Date:  2018-04-23

6.  Study of toxoplasmosis and toxocariasis in patients suffering from ophthalmic disorders using serological and molecular methods.

Authors:  Jasem Saki; Elham Eskandari; Mostafa Feghhi
Journal:  Int Ophthalmol       Date:  2020-05-18       Impact factor: 2.031

7.  Serological and Molecular Diagnosis of Toxoplasma gondii Infections in Thalassemia Patients.

Authors:  Hooman Hanifehpour; Seyed Kamal Samsam Shariat; Mohammad Saleh Ghafari; Farnaz Kheirandish; Vafa Saber; Shirzad Fallahi
Journal:  Iran J Parasitol       Date:  2019 Jan-Mar       Impact factor: 1.012

8.  Detection of anti-Toxoplasma gondii antibodies in chronic myeloid leukemia and acute myeloid leukemia patients.

Authors:  Mohammad Javad Gharavi; Mona Roozbehani; Zienat Mandeh
Journal:  Vet World       Date:  2017-09-13

9.  Toxoplasma gondii: Preventive and therapeutic effects of morphine and evaluation of treatment parameters of tachyzoites and infected macrophages in vitro and in a murine model.

Authors:  Leila Zaki; Fatemeh Ghaffarifar; Zohreh Sharifi; John Horton; Javid Sadraei
Journal:  EXCLI J       Date:  2020-04-20       Impact factor: 4.068

10.  Diagnosis of Acute Toxoplasmosis by IgG and IgM Antibodies and IgG Avidity in Pregnant Women from Mashhad, Eastern Iran.

Authors:  Karam Sharifi; Bibi Razieh Hosseini Farash; Fatemeh Tara; Azad Khaledi; Karim Sharifi; Seyed Ali Akbar Shamsian
Journal:  Iran J Parasitol       Date:  2019 Oct-Dec       Impact factor: 1.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.